$MLM

Martin Marietta Materials (MLM) stock hit a 52-week low of $491.41, down 31% from its high. The company faces sector challenges but has raised dividends for 10 years. It issued $5.5B in notes for Lhoist North America acquisition, expected to close in Q3 2026. Analysts have mixed ratings, with JPMorgan upgrading to Overweight and Truist Securities maintaining Buy.

MARTIN MARIETTA MATERIALS INC (MLM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement On September 15, 2026, Martin Marietta Materials, Inc., (the “Corporation”) and its wholly - owned subsidiary, Martin Marietta Funding LLC (“MM Funding”), entered into the Eighteenth Amendment (the “Eighteenth Amendment”) to i

Carmeuse acquired 80% of Argentina's Caleras San Juan, expanding lime production capacity. Mississippi Lime Company partnered with Fortera for low-carbon cement. SigmaRoc bought Dolomitas in Lithuania for €118m. Martin Marietta completed its acquisition of Lhoist North America. Breedon Group and Votorantim Cimentos España announced executive appointments. US removed tariffs on Canadian cement imports. Heidelberg Materials plans to close its Ranville plant in France.

J.P. Morgan recommends Reformation (REF) and Martin Marietta Materials (MLM) as investment opportunities. REF, a sustainable fashion company, reported Q2 revenue of $155.2M, up 24%, and has a $21 price target. MLM, a construction materials supplier, completed a $13.5B acquisition and reported Q2 revenue of $1.9B, up 21%. Both stocks have positive analyst ratings.

Martin Marietta Materials (MLM) faces challenges from weaker construction demand and rising costs, with potential share dilution from the Lhoist North America acquisition. Analysts project $8.8B revenue and $1.6B earnings by 2029, but risks include higher leverage and margin pressure. Current net margin is 13.9%, down from 16.1%.

High-grade debt issuance surged to $57 billion in the first two days of September, potentially leading to a fourth consecutive monthly record. September's supply could exceed $200 billion, surpassing last year's $189 billion. Key deals include GlaxoSmithKline's $6.5 billion offering and UBS's $6 billion print. AI debt spreads remain tight, but yields have risen. M&A-related debt issuance increased to 20% in August, the highest since May.

Analysts upgraded five companies: Barclays raised Sagimet Biosciences (SGMT) to Overweight, targeting $18. B of A upgraded Figure Technology (FIGR) to Neutral, targeting $49. UBS upgraded Illumina (ILMN) to Buy, targeting $260. Wells Fargo upgraded Martin Marietta (MLM) to Overweight, targeting $609. UBS also upgraded Waters (WAT) to Buy, targeting $490.

Wells Fargo upgraded Martin Marietta Materials (MLM) to Overweight, raising its price target to $609 from $581. The company's stock is trading at $511.44, 24.2% below its GF Value™ of $674.78, indicating undervaluation. MLM has a GF Score™ of 90/100, reflecting strong growth and profitability. The upgrade follows MLM's $13.5 billion acquisition of Lhoist North America, expected to drive margin expansion.

Analysts made several rating changes: TD Cowen initiated Faeth Therapeutics as buy, Barclays upgraded Sagimet Biosciences to overweight, JPMorgan upgraded Lithium Americas to overweight, and more. Price targets were also adjusted for companies like Affirm, Robinhood, and First Solar.

Carlisle (CSL) reported $1.57B revenue, up 8.3% YoY, beating estimates. Armstrong World (AWI) reported $472M revenue, up 11.2% YoY, exceeding expectations. Vulcan Materials (VMC) reported $2.16B revenue, up 2.5% YoY, surpassing estimates. Martin Marietta Materials (MLM) reported $1.95B revenue, up 21% YoY, topping expectations. Stocks reacted variably post-earnings.